Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $93.7 million.

  • Pliant Therapeutics' Cash & Equivalents rose 1773.01% to $93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.7 million, marking a year-over-year increase of 1773.01%. This contributed to the annual value of $71.2 million for FY2024, which is 1257.87% up from last year.
  • As of Q3 2025, Pliant Therapeutics' Cash & Equivalents stood at $93.7 million, which was up 1773.01% from $86.8 million recorded in Q2 2025.
  • Over the past 5 years, Pliant Therapeutics' Cash & Equivalents peaked at $114.3 million during Q1 2024, and registered a low of $25.1 million during Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $57.7 million (2023), whereas its average is $64.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 8027.97% in 2021, then surged by 21503.15% in 2023.
  • Pliant Therapeutics' Cash & Equivalents (Quarter) stood at $51.7 million in 2021, then plummeted by 34.8% to $33.7 million in 2022, then surged by 87.72% to $63.2 million in 2023, then increased by 12.58% to $71.2 million in 2024, then soared by 31.67% to $93.7 million in 2025.
  • Its last three reported values are $93.7 million in Q3 2025, $86.8 million for Q2 2025, and $91.9 million during Q1 2025.